- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03224832
Pancreatoduodenectomy With Mesopancreas Dissection.A Prospective Study Comparing Artery-first Approach Versus Standard Approach
The definitions for R0 and R1 margin status after resection for pancreatic cancer are controversial.Various studies showed the rate of noncurative resections of 15- 35 % but with modified pathological examination (R1/R2) revealed the rate of R1 resection was higher ranging from 76-85 % .
Verbeke CS etal.
- Whether this discrepancy was caused by incomplete lymphnode dissection, perineural dissection and improper pathological examination was not yet known.
- Perineural invasion was detected in 77 % of specimens of resected pancreatic cancers.
So the researchers emphasized the need of new surgical classification involving mesopancreas. It can be considered as an anatomical space bounded anteriorly by the the posterior surface of the pancreatic neck, posteriorly by the pancreaticoduodenal coalescence fascia, medially by the mesenteric vessels with -nerves, lymphatics and vessels as its contents.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
A Controlled clinical trial of pancreatoduodenectomy with mesopancreas dissection.A Prospective study comparing artery-first versus standard approach.
Target population:
-All cases of malignant obstructive jaundice within the above criteria.
Sample size:
- It will be conventional sample size of about 40 cases minimum about 20 case for each group of the both procedures
- Techniques:
- The procedure at Assiut university hospital consists of artery-first with l dissection at the origin of the superior mesenteric artery and the celiac trunk all along their right side of the vessels versus standard approach.
- This allows a complete clearance of retro- pancreatic tissues.
- -En bloc resection of the primary tumor and regional lymph nodes through complete excision of the mesopancreatic plane, utilizing the artery-first approach.
- -The mesopancreatic plane consists of the pancreas head, the uncinate process of the pancreas, and the meso-pancreatoduodenum.
- All the tissues that lay in this triangular space (SMA down, CT up, and SMV-PV anterior) is cleared.
Then the investigators continue the dissection along the right then anterior surface of the SMV and PV until reaching the dissected posterior surface the neck of the pancreas .
- Last step is the division of the neck of the pancreas.
- After the specimen is removed and before it is sent to the pathology the investigators put mark on each boundary of the specimen one towards SMA, another towards PV/SMV area and the last towards the posterior surface of the mesopancreas.
- This can guide the pathologist to identify the retro pancreatic margins and define whenever there is an R1 resection the exact area of invasion. Microscopic margin involvement (R1) will be defined as tumor within 1 mm of resection margin.
While in standard approach at first kocharization of the duodenum ,then starting to asses the tunnel under the neck of the pancreas whether tumor infilterating PV/SMV axis and if not the investigators cut the neck of pancreas early in the procedure then continue to dissect the uncinate process and control pancreatoduodenal vessels and draining lymph nodes and LNS around portal vein and up to hepatic artery and we will add to the standard procedure the previously defined mesopancreatic triangle dissection which lies between SMA caudal, Coeliac artery cranial and PV/SMV axis anterior and the specimen will be marked and sent as previous to pathology.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Mostafa Ali Sayed, PHD
- Phone Number: 0201095937131
- Email: mostafa.ali270927@yahoo.com
Study Contact Backup
- Name: Faculty of Medicine-Assiut University -Assiut-Egypt Faculty of Medicine-Assiut University -Assiut-Egypt
- Phone Number: 0201095937131
Study Locations
-
-
-
Assiut, Egypt
- Assiut University
-
Contact:
- Assiut university
- Phone Number: 0201095937131
- Email: mostafa.ali270927@yahoo.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- All cases of resectable periampullary carcinoma
- surgically fit accordying to ASA
Exclusion Criteria:
- Surgically unfit cases according to ASA.
- locally advanced irresectable cases
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: group 1
group 1 will be Pancreatoduodenectomy With Mesopancreas.
Artery-first Approach
|
Dissection at the origin of the superior mesenteric artery and the celiac trunk all along their right side of the vessels. -En bloc resection of the primary tumor and regional lymph nodes through complete excision of the mesopancreatic plane, utilizing the artery-first approach.
All the tissues that lay in this triangular space (SMA down, CT up, and SMV-PV anterior) is cleared. Then the investigators continue the dissection along the right then anterior surface of the SMV and PV until reaching the dissected posterior surface the neck of the pancreas . Last step is the division of the neck of the pancreas. After the specimen is removed and before it is sent to the pathology we put mark on each boundary of the specimen one towards SMA, another towards PV/SMV area and the last towards the posterior surface of the mesopancreas.
Other Names:
|
Experimental: group2
group2 will be Pancreatoduodenectomy With Mesopancreas Dissection.
Standard Approach
|
In standard approach after kocharization of the duodenum the investigators start to asses the tunnel under the neck of the pancreas whether tumor infilterating PV/SMV axis and if not we cut the neck of pancreas early in the procedure then we continue to dissect the uncinate process and control pancreatoduodenal vessels and draining lymph nodes and LNS around portal vein and up to hepatic artery and we will add to the standard procedure the previously defined mesopancreatic triangle dissection which lies between SMA caudal, Coeliac artery cranial and PV/SMV axis anterior and the specimen will be marked and sent as previous to pathology.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Time to judge resectability intra operative and operative time for each procedure.
Time Frame: up to 2 weeks postoperative data will be available
|
Time to judge resectability intra operative and operative time for each procedure usually lasts from 3 to 12 hours(operative time)
|
up to 2 weeks postoperative data will be available
|
Blood loss in both procedures.
Time Frame: up to 2 weeks postoperative data will be available
|
Blood loss in both procedures in cc usually lasts from 3 to 12 hours(operative time)
|
up to 2 weeks postoperative data will be available
|
Pathological data
Time Frame: up to 2 weeks postoperative data will be available
|
( cancer type, grade,LNS number and focus on infiltration of mesopancreas(R0 free margin more than 1 mm R1 +margin or infiltration less than 1mm.
|
up to 2 weeks postoperative data will be available
|
Mortality rate.
Time Frame: up to 15 months after each case
|
number of deaths intraoperative and immediate postoperative
|
up to 15 months after each case
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
- Short term postoperative survival 15 month after the last case of the study
Time Frame: 15 month after the last case of the study
|
- Short term postoperative survival 15 month after the last case of the study
|
15 month after the last case of the study
|
locoregional recurrence
Time Frame: 15 month after the last case of the study
|
locoregional recurrence follow up ct abdomen every 4 months postoperative till 15 months postoperative
|
15 month after the last case of the study
|
Postoperative complications
Time Frame: 15 month after the last case of the study
|
Postoperative complications especially diarrhea
|
15 month after the last case of the study
|
Collaborators and Investigators
Sponsor
Publications and helpful links
General Publications
- Adham M, Singhirunnusorn J. Surgical technique and results of total mesopancreas excision (TMpE) in pancreatic tumors. Eur J Surg Oncol. 2012 Apr;38(4):340-5. doi: 10.1016/j.ejso.2011.12.015. Epub 2012 Jan 20.
- Kayahara M, Nagakawa T, Ueno K, Ohta T, Takeda T, Miyazaki I. An evaluation of radical resection for pancreatic cancer based on the mode of recurrence as determined by autopsy and diagnostic imaging. Cancer. 1993 Oct 1;72(7):2118-23. doi: 10.1002/1097-0142(19931001)72:73.0.co;2-4.
- Gockel I, Domeyer M, Wolloscheck T, Konerding MA, Junginger T. Resection of the mesopancreas (RMP): a new surgical classification of a known anatomical space. World J Surg Oncol. 2007 Apr 25;5:44. doi: 10.1186/1477-7819-5-44.
Helpful Links
- Clearance of the retropancreatic margin in pancreatic carcinomas: total mesopancreas excision or extended lymphadenectomy? [Eur J Surg Oncol. 2012]
- The frequency of retroperitoneal recurrence of carcinoma of the head of the pancreas suggests that retroperitoneal resection,
- The aim to ensure the greatest possible distance from the retropancreatic lymphatic tissue which drains the carcinomatous focus can be achieved in patients with pancreatic cancer only by complete resection of the mesopancreas (RMP).
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- mas2017
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Prospective comparative study between Artery-first versus standard pancreatoduodenectomy with mesopancreas dissection.
Evaluating perioperative outcomes:Blood loss,Operative time(+/-time to judge resectability),Pathological data(specially those related to mesopancreas) morbidity and mortality
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Periampullary Carcinoma Resectable
-
Xuzhou Medical UniversityThe Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical...UnknownPancreaticoduodenectomy | Periampullary Carcinoma ResectableChina
-
Mansoura UniversityCompletedPeriampullary Carcinoma ResectableEgypt
-
Tongji HospitalCompletedResectable Lesions Located in the Pancreatic Head or Periampullary Region
-
Universitätsklinikum Hamburg-EppendorfCompletedChronic Pancreatitis | Resectable Pancreatic Head Neoplasm | Resectable Periampullary NeoplasmGreece, Germany, Italy
-
Weill Medical College of Cornell UniversityUnknownPancreatic Cancer | Pancreatic Adenocarcinoma | Periampullary Cancer | Biliary Tract Neoplasms | Unresectable Pancreatic Cancer | Biliary Duct Obstruction | Periampullary Carcinoma Non-ResectableUnited States
-
Hospital de Clinicas de Porto AlegreCoordenação de Aperfeiçoamento de Pessoal de Nível Superior.; Conselho Nacional... and other collaboratorsCompletedPeriampullary Carcinoma NosBrazil
-
Southwest Hospital, ChinaUnknownPeriampullary Carcinoma NosChina
-
Govind Ballabh Pant HospitalRecruitingPeriampullary CarcinomaIndia
-
Tongji HospitalShanxi Province Cancer Hospital; Chongqing University Cancer Hospital; Fudan... and other collaboratorsNot yet recruitingPeriampullary AdenocarcinomaChina
-
Yonsei UniversityUnknown
Clinical Trials on Artery-first Approach
-
Thomas Jefferson UniversityRecruitingLung Non-Small Cell Carcinoma | Stage III Lung Cancer AJCC v8 | Stage II Lung Cancer AJCC v8 | Stage I Lung Cancer AJCC v8United States
-
Asan Medical CenterRecruitingRecurrence Tumor | Pancreatic Cancer, Adult | Surgery Site Fistula | Margin, Tumor-FreeKorea, Republic of
-
West China HospitalUnknownLung Cancer | Surgery | Circulating Tumor CellChina
-
Sichuan Cancer Hospital and Research InstituteSichuan Provincial People's Hospital; The Second People's Hospital of ChengduNot yet recruiting
-
Shenzhen People's HospitalRecruitingAcute Coronary Syndrome | Outcome, Fatal | Procedural ComplicationChina
-
Centre for Evidence-Based Practice, BelgiumBelgian Red Cross; Rwanda Red CrossActive, not recruitingEmergencies | Injuries | Illness PhysicalRwanda
-
Instituto Nacional de Cardiologia Ignacio ChavezCompletedRadial Artery OcclusionMexico
-
Heidelberg UniversityUnknownPancreatic Head CancerGermany
-
Ibn Jazzar HospitalCompleted
-
NYU Langone HealthCompletedCoronary Artery DiseaseUnited States